Cholesterol Drug Zetia Doesn't Cut Heart Attack Risk: Study(Page 3) "If there is no apparent clinical benefit, why take a drug that cost three or four times more?" Findlay said in a statement. "Most people do not need that magnitude of cholesterol reduction anyway." Sales of Zetia and Vytorin totaled $3.7 billion in the nine months ending Sept. 30, up 33 percent from a year ago. Analysts estimate that about 70 percent of Schering-Plough's earnings depend on the drugs, the Times noted. More information There's more on lowering cholesterol at the American Heart Association. Related Links
advertisement
| ||
What's HOTGet our free newsletter
PR Newswire |
 |
The drkoop.com URL and web site are not associated with C. Everett Koop, M.D., former Surgeon General of the United States.
By using this service, you accept our Terms of Use. Please read them. The consumer health information on drkoop.com is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2004-2008. The HealthCentral Network, Inc. All rights reserved.